CME/Answers : Hypertension and the COVID-19 Pandemic: What to Consider in Medical Practice
CME/Answers: Hypertension and the COVID-19 Pandemic: What to Consider in Medical Practice Abstract. The COVID-19 pandemic represents a major public health problem. A fraction of the population is at increased risk of developing complications of this disease, in particular older subjects as well as diabetic, obese and hypertensive patients. With regard to patients with high blood pressure, the existence of an increased risk remains to be confirmed in large controlled trials. So far the findings regarding this question are reassuring, whether these patients are treated or not. There seems to be no reason to worry when using blockers of the renin-angiotensin system. The observations available to date suggest that COVID-19 vaccine can be administered safely to hypertensive patients. In conclusion, there is no reason to implement changes in the care of hypertensive patients due to the pandemic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:110 |
|---|---|
| Enthalten in: |
Praxis - 110(2021), 3 vom: 16., Seite 141-142 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
CME/Antworten: Hypertonie und die COVID-19-Pandemie: Was in der medizinischen Praxis zu beachten ist |
|---|
| Beteiligte Personen: |
Wuerzner, Grégoire [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.03.2021 Date Revised 04.03.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1024/1661-8157/a003636 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322106206 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322106206 | ||
| 003 | DE-627 | ||
| 005 | 20231225181328.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1024/1661-8157/a003636 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1073.xml |
| 035 | |a (DE-627)NLM322106206 | ||
| 035 | |a (NLM)33653105 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Wuerzner, Grégoire |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CME/Answers |b Hypertension and the COVID-19 Pandemic: What to Consider in Medical Practice |
| 246 | 3 | 3 | |a CME/Antworten: Hypertonie und die COVID-19-Pandemie: Was in der medizinischen Praxis zu beachten ist |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2021 | ||
| 500 | |a Date Revised 04.03.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a CME/Answers: Hypertension and the COVID-19 Pandemic: What to Consider in Medical Practice Abstract. The COVID-19 pandemic represents a major public health problem. A fraction of the population is at increased risk of developing complications of this disease, in particular older subjects as well as diabetic, obese and hypertensive patients. With regard to patients with high blood pressure, the existence of an increased risk remains to be confirmed in large controlled trials. So far the findings regarding this question are reassuring, whether these patients are treated or not. There seems to be no reason to worry when using blockers of the renin-angiotensin system. The observations available to date suggest that COVID-19 vaccine can be administered safely to hypertensive patients. In conclusion, there is no reason to implement changes in the care of hypertensive patients due to the pandemic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Blocker des Renin-Angiotensin-Systems | |
| 650 | 4 | |a Bluthochdruck | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 vaccine | |
| 650 | 4 | |a Hypertonie | |
| 650 | 4 | |a Risikofaktoren | |
| 650 | 4 | |a antihypertensive Therapie | |
| 650 | 4 | |a antihypertensive therapy | |
| 650 | 4 | |a blockers of the renin-angiotensin system | |
| 650 | 4 | |a bloqueurs du système rénine-angiotensine | |
| 650 | 4 | |a facteurs de risque | |
| 650 | 4 | |a hypertension | |
| 650 | 4 | |a hypertension artérielle | |
| 650 | 4 | |a risk factors | |
| 650 | 4 | |a traitement antihypertenseur | |
| 650 | 4 | |a vaccination Covid-19 | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Waeber, Bernard |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Praxis |d 1994 |g 110(2021), 3 vom: 16., Seite 141-142 |w (DE-627)NLM074578928 |x 1661-8157 |7 nnns |
| 773 | 1 | 8 | |g volume:110 |g year:2021 |g number:3 |g day:16 |g pages:141-142 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1024/1661-8157/a003636 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 110 |j 2021 |e 3 |b 16 |h 141-142 | ||